Heparan sulfate proteoglycans and heparanase - partners in osteolytic tumor growth and metastasis

被引:174
作者
Sanderson, RD [1 ]
Yang, Y
Suva, LJ
Kelly, T
机构
[1] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Little Rock, AR USA
[3] Univ Arkansas Med Sci, Dept Orthopaed Surg, Little Rock, AR USA
[4] Univ Arkansas Med Sci, Ctr Orthopaed Res, Little Rock, AR USA
基金
美国国家卫生研究院;
关键词
heparan sulfate proteoglycans; heparanase; tumor growth;
D O I
10.1016/j.matbio.2004.08.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review summarizes a series of studies demonstrating that heparan sulfate proteoglycans act to promote the growth and metastasis of myeloma and breast tumors, two tumors that home to, and grow within, bone. Much of the growth-promoting effect of proteoglycans in these tumors may reside in the shed form of syndecan-1 that acts to favorably condition the tumor microenvironment. Moreover, the interplay between heparan sulfate and the extracellular enzyme heparanase-1 also has important regulatory implications. Recent studies indicate that the activity of heparanase, which likely releases heparin sulfate-bound growth factors and generates highly active heparan sulfate fragments, also promotes growth and metastasis of myeloma and breast tumors. Understanding the role of heparan sulfate and heparanase in the regulation of tumor behavior may lead to new therapeutic approaches for treating cancer. (c) 2004 Elsevier B.V./International Society of Matrix Biology. All rights reserved.
引用
收藏
页码:341 / 352
页数:12
相关论文
共 113 条
[1]   QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling [J].
Ai, XB ;
Do, AT ;
Lozynska, O ;
Kusche-Gullberg, M ;
Lindahl, U ;
Emerson, CP .
JOURNAL OF CELL BIOLOGY, 2003, 162 (02) :341-351
[2]   Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice [J].
Alexander, CM ;
Reichsman, F ;
Hinkes, MT ;
Lincecum, J ;
Becker, KA ;
Cumberledge, S ;
Bernfield, M .
NATURE GENETICS, 2000, 25 (03) :329-332
[3]  
Anderson KC, 2002, MOL CANCER THER, V1, P1361
[4]   High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis [J].
Barbareschi, M ;
Maisonneuve, P ;
Aldovini, D ;
Cangi, MG ;
Pecciarini, L ;
Mauri, FA ;
Veronese, S ;
Caffo, O ;
Lucenti, A ;
Palma, PD ;
Galligioni, E ;
Doglioni, C .
CANCER, 2003, 98 (03) :474-483
[5]   Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions [J].
Bayer-Garner, IB ;
Sanderson, RD ;
Dhodapkar, MV ;
Owens, RB ;
Wilson, CS .
MODERN PATHOLOGY, 2001, 14 (10) :1052-1058
[6]   The syndecan-1 ectodomain regulates αvβ3 integrin activity in human mammary carcinoma cells [J].
Beauvais, DLM ;
Burbach, BJ ;
Rapraeger, AC .
JOURNAL OF CELL BIOLOGY, 2004, 167 (01) :171-181
[7]   Syndecan-1-mediated cell spreading requires signaling by αvβ3 integrins in human breast carcinoma cells [J].
Beauvais, DM ;
Rapraeger, AC .
EXPERIMENTAL CELL RESEARCH, 2003, 286 (02) :219-232
[8]   Tumor attenuation by combined heparan sulfate and polyamine depletion [J].
Belting, M ;
Borsig, L ;
Fuster, MM ;
Brown, JR ;
Persson, L ;
Fransson, LÅ ;
Esko, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (01) :371-376
[9]  
Bendre MS, 2002, CANCER RES, V62, P5571
[10]   Functions of cell surface heparan sulfate proteoglycans [J].
Bernfield, M ;
Götte, M ;
Park, PW ;
Reizes, O ;
Fitzgerald, ML ;
Lincecum, J ;
Zako, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 :729-777